Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravagalimab in primary Sjogren's Syndrome
NCT05217472Phase 2Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Mar 2020
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial comparing Ravagalimab with Placebo (2 arms). Primary endpoint: Change From Baseline in EULAR Sjogren's Syndrome Disease Activity Index at Week 24. Planned start Mar 2020; status: withdrawn.
02
Drugs
ravagalimab
Beyond the preview
Go deeper on NCT05217472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05217472.